Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

The Lyme disease testing market has seen remarkable growth in recent years, driven by increasing awareness and advances in diagnostic technology. As the prevalence of tick-borne illnesses continues to rise globally, the demand for accurate and timely Lyme disease testing is expected to grow significantly. Let’s examine the current market status, key growth factors, emerging innovations, and the competitive landscape shaping this important healthcare sector.

Steady Expansion in Lyme Disease Testing Market Size and Future Outlook

The market for Lyme disease testing has experienced strong growth, with its size projected to increase from $10.68 billion in 2025 to $11.67 billion in 2026, representing a compound annual growth rate (CAGR) of 9.3%. This positive momentum during the past years is linked to factors such as the rising incidence of Lyme disease, limited awareness around early diagnosis, continued reliance on traditional serological testing methods, an increase in hospital-based diagnostics, and expanding research efforts focused on tick-borne infections. Looking ahead, the market is expected to expand further, reaching $16.46 billion by 2030 with a CAGR of 9.0%. This sustained growth will be driven by the adoption of AI-assisted diagnostic tools, increased availability of home-testing kits, broader use of multi-disease panels, enhanced government funding for surveillance programs, and the integration of cloud-based laboratory data management systems. Key trends in the forecast period also include the growth of point-of-care testing, home-based Lyme disease diagnostics, rapid test kit adoption, multi-pathogen tick-borne panels, and the development of personalized diagnostic protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp

Increasing Prevalence of Tick-Borne Illnesses Fueling Lyme Disease Testing Demand

One of the primary factors propelling the Lyme disease testing market is the growing occurrence of tick-borne illnesses worldwide. These diseases are transmitted to humans through bites from infected ticks, which are commonly found in grassy, wooded, or rural regions. The expansion of tick habitats, largely attributed to climate change, has heightened exposure risks and infection rates among populations. This increased prevalence of tick-borne diseases raises the demand for effective Lyme disease testing, as early detection is crucial for managing and treating infections promptly. For example, in March 2025, the U.S. Centers for Disease Control and Prevention (CDC) reported over 89,000 Lyme disease cases in 2023—a number that highlights the persistent burden of tick-related illnesses and reinforces the need for comprehensive testing solutions.

Detailed Segmentation of the Lyme Disease Testing Market

The Lyme disease testing market is comprehensively segmented to cover various testing types, methods, disease stages, sample types, and end-users. Key test types include serological tests, nucleic acid tests, urine antigen tests, and other emerging test types. Testing methodologies encompass Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), and other cutting-edge technologies. The market also considers disease stages such as early Lyme disease, disseminated Lyme disease, chronic Lyme disease, and asymptomatic detection. Sample types analyzed include blood, urine, cerebrospinal fluid (CSF), and other blood derivatives. End-user categories consist of hospitals and clinics, diagnostic laboratories, home care settings, research institutions, and public health organizations. Further subsegments break down serological tests into ELISA, Western Blot, Immunofluorescence Assay (IFA), and Line Immunoassay (LIA); nucleic acid tests into PCR, Loop-Mediated Isothermal Amplification (LAMP), and Next-Generation Sequencing (NGS); urine antigen tests into lateral flow assay, enzyme immunoassay (EIA), and immunoblot urine tests; and other tests including culture-based assays, tick-borne co-infection panels, and AI-assisted diagnostic tools.

Access The Complete Lyme Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Innovative Diagnostic Technologies Shaping the Lyme Disease Testing Market

Leading players in the Lyme disease testing industry are heavily investing in the development of advanced diagnostic tools aimed at improving test accuracy, reducing response times, and enabling early detection of the disease. These diagnostic technologies identify specific antibodies, antigens, or genetic material related to the Borrelia burgdorferi bacteria, the causative agent of Lyme disease. For example, in August 2024, UK-based biotechnology firm EpitogenX Ltd. introduced a state-of-the-art Lyme Disease Diagnostic Kit utilizing their proprietary EpitoGen platform. This ELISA-based assay features approximately 120 distinct Borrelia epitopes, providing high sensitivity and specificity for strain-specific detection. Designed for research use, it supports customization for various laboratory settings, enhancing detection precision and enabling deeper understanding of Lyme disease.

Recognized Industry Leaders in the Lyme Disease Testing Market

The competitive environment of the Lyme disease testing market includes several prominent companies such as Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., and Seegene Inc. These organizations are actively advancing diagnostic technologies and expanding service offerings to meet growing market demand.

Geographical Distribution and Growth Patterns in the Lyme Disease Testing Market

In 2025, North America held the largest share of the Lyme disease testing market, driven by robust healthcare infrastructure and high disease prevalence. Meanwhile, the Asia-Pacific region is anticipated to register the fastest growth during the forecast period due to rising awareness, expanding healthcare access, and increasing government initiatives focused on infectious disease monitoring. The market study encompasses key regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a comprehensive view of the global Lyme disease testing landscape.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model